drugset / Trial / NCT00535665

Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine

NCT00535665 ↗

RandomizedParallel-groupQuadruple-blindPrevention

Summary

A single center, randomized and double-blind phase II clinical trial is to be conducted in adults to evaluate the safety and immunogenicity of an inactivated pandemic influenza vaccine (whole-virion, aluminium-adjuvanted).

Timeline

Start
2007-09
Primary completion
—
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject pandemic influenza vaccine (H5N1 strain NIBRG-14) Vaccine 5 ug —
Subject pandemic influenza vaccine (H5N1 strain NIBRG-14) Vaccine 10 ug —
Subject pandemic influenza vaccine (H5N1 strain NIBRG-14) Vaccine 15 ug —

Indications